



**ARSEUS**  
Driving superior care

## Press Release

Regulated information

### DISCLOSURE OF RECEIVED NOTIFICATIONS

Waregem (Belgium) / Rotterdam (Netherlands)<sup>1</sup>, 13 August 2013 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received notifications from BNP Paribas Investment Partners SA and from Mr Van Jeveren on 8 August concerning the acquisition or disposal of voting securities.

The shareholdings of BNP Paribas Investment Partners SA now exceed the disclosure threshold of 5%. The shareholdings of Mr Van Jeveren have fallen below the disclosure threshold of 3% through the disposal of voting securities. Van Jeveren used the proceeds for the exercise of stock options in April 2013.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 13 August 2013 is as follows:

	Number of shares	% of effective voting rights
EnHold NV	8,166,908	26.04%
Alychlo NV / Coucke	3,528,080	11.25%
BNP Paribas Investment Partners SA	1,609,182	5.13%
Arseus NV (treasury shares)	631,378	2.01%
Public	17,422,810	55.57%
<b>Total</b>	<b>31,358,358</b>	<b>100.00%</b>

The original notification forms are available at [www.arseus.com](http://www.arseus.com).

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

---

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

**For more information:**

Constantijn van Rietschoten  
Director of Corporate Communications  
+31 88 33 11 222 (Office)  
+31 6 53 69 15 85 (Mobile)  
[constantijn.van.rietschoten@arseus.com](mailto:constantijn.van.rietschoten@arseus.com)

**Arseus profile**

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.